🎶🎵 ...And she went down swingin'... 🎶🎵
Posting my cancer story so that I have a place to refer folks interested in my cancer backstory.
Winter is over moving day! Orchids out of the Vanda House and back outside where we can enjoy them. So many blooming right now. This is Motes Arorbs putting on a show.
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study - Xu
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
GNGT1 remodels the tumor microenvironment and promotes immune escape through enhancing tumor stemness and modulating the fibrinogen beta chain-neutrophil extracellular trap signaling axis in lung adenocarcinoma - Fan
Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients—A Multicenter Analysis
Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma a real-world retrospective study
SMARCA4/BRG1-deficient non-small cell lung cancer: clinical, imaging, pathological features, and follow-up results of 23 patients - Wumener
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study | BMC Cancer
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer - Carroll
Frontiers | Prediction of EGFR Mutations in Non-Small Cell Lung Cancer: A Nomogram Based on 18 F-FDG PET and Thin-Section CT Radiomics with Machine Learning
Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors - Watanabe
The NcRNA/Wnt axis in lung cancer: oncogenic mechanisms, remarkable indicators and therapeutic targets | Journal of Translational Medicine
Video-assisted mediastinocopic lymphadenectomy (VAMLA) for restaging clinical N2–3 non-small cell lung cancer (NSCLC) after neoadjuvant treatment - Reig-Oussedik
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
Lobectomy plus lobe-specific lymphadenectomy as the minimum standards of curative resection for hypermetabolic clinical stage IA non-small cell lung cancer - Li
Frontiers | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance - Hua
Clinical effectiveness of Anlotinib combined with PD-1 inhibitors in treating advanced non-small-cell lung carcinoma (pdf)
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Multidimensional bioinformatics perspective on smoking-linked driver genes and immune regulatory mechanisms in non-small cell lung cancer | Journal of Translational Medicine
Methodological aspects of studies on survival after immunotherapy in stage IV non-small cell lung cancer - Tuminello
